Meyka Pro banner
Vir Biotechnology, Inc.

Vir Biotechnology, Inc. Fundamental Analysis (NASDAQ: VIR)

VIR●NASDAQ
HealthcareBiotechnology
$9.16
$0.80(8.03%)
U.S. Market is Open · 10:31

Vir Biotechnology, Inc. Fundamental Analysis (NASDAQ: VIR)

Vir Biotechnology, Inc. (NASDAQ: VIR) shows weak financial fundamentals with a PE ratio of -7.78, profit margin of -61.03%, and ROE of -21.38%. The company generates $0.3B in annual revenue with weak year-over-year growth of -7.61%.

Key Strengths

Cash Position28.26%
PEG Ratio-0.07
Current Ratio6.30

Areas of Concern

ROE-21.38%
Operating Margin-69.76%
We analyze VIR's fundamental strength across five key dimensions.

The stock receives a Fundamental Health Score of -47.0/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.

Fundamental Health Score

F
-47.0/100

We analyze VIR's fundamental strength across five key dimensions:

Efficiency Score

Weak

VIR struggles to generate sufficient returns from assets.

ROA > 10%
-16.62%

Valuation Score

Excellent

VIR trades at attractive valuation levels.

PE < 25
-7.78
PEG Ratio < 2
-0.07

Growth Score

Moderate

VIR shows steady but slowing expansion.

Revenue Growth > 5%
-7.61%
EPS Growth > 10%
17.49%

Financial Health Score

Excellent

VIR maintains a strong and stable balance sheet.

Debt/Equity < 1
0.10
Current Ratio > 1
6.30

Profitability Score

Weak

VIR struggles to sustain strong margins.

ROE > 15%
-2138.42%
Net Margin ≥ 15%
-61.03%
Positive Free Cash Flow
No

Key Financial Metrics

Is VIR Expensive or Cheap?

P/E Ratio

VIR trades at -7.78 times earnings. This suggests potential undervaluation.

-7.78

PEG Ratio

When adjusting for growth, VIR's PEG of -0.07 indicates potential undervaluation.

-0.07

Price to Book

The market values Vir Biotechnology, Inc. at 1.84 times its book value. This may indicate undervaluation.

1.84

EV/EBITDA

Enterprise value stands at -9.23 times EBITDA. This is generally considered low.

-9.23

How Well Does VIR Make Money?

Net Profit Margin

For every $100 in sales, Vir Biotechnology, Inc. keeps $-61.03 as profit after all expenses.

-61.03%

Operating Margin

Core operations generate -69.76 in profit for every $100 in revenue, before interest and taxes.

-69.76%

ROE

Management delivers $-21.38 in profit for every $100 of shareholder equity.

-21.38%

ROA

Vir Biotechnology, Inc. generates $-16.62 in profit for every $100 in assets, demonstrating efficient asset deployment.

-16.62%

Following the Money - Real Cash Generation

Operating Cash Flow

Vir Biotechnology, Inc. generates limited operating cash flow of $-142.68M, signaling weaker underlying cash strength.

$-142.68M

Free Cash Flow

Vir Biotechnology, Inc. generates weak or negative free cash flow of $-143.49M, restricting financial flexibility.

$-143.49M

FCF Per Share

Each share generates $-0.84 in free cash annually.

$-0.84

FCF Yield

VIR converts -8.55% of its market value into free cash.

-8.55%

Financial Ratios Analysis

Valuation Ratios

P/E Ratio

Price to earnings ratio

-7.78

vs 25 benchmark

PEG Ratio

Price/earnings to growth ratio

-0.07

vs 25 benchmark

P/B Ratio

Price to book value ratio

1.84

vs 25 benchmark

P/S Ratio

Price to sales ratio

5.50

vs 25 benchmark

Financial Health

Debt/Equity

Total debt to shareholders' equity

0.10

vs 25 benchmark

Current Ratio

Current assets to current liabilities

6.30

vs 25 benchmark

Efficiency Ratios

ROE

Return on equity percentage

-0.21

vs 25 benchmark

ROA

Return on assets percentage

-0.17

vs 25 benchmark

ROCE

Return on capital employed

-0.20

vs 25 benchmark

How VIR Stacks Against Its Sector Peers

MetricVIR ValueSector AveragePerformance
P/E Ratio-7.7830.85 Better (Cheaper)
ROE-21.38%473.00% Weak
Net Margin-61.03%5192.00% Weak
Debt/Equity0.100.12 Neutral
Current Ratio6.305.76 Strong Liquidity
ROA-16.62%-1414.00% (disorted) Weak

VIR outperforms its industry in 2 out of 6 key metrics, but lagging in ROE.

Historical Growth Performance

5-Year Growth Trajectory

This section reviews Vir Biotechnology, Inc.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.

Revenue CAGR

-22.78%

Industry Style: Defensive, Growth, Innovation

Declining

EPS CAGR

-26.15%

Industry Style: Defensive, Growth, Innovation

Declining

FCF CAGR

-76.51%

Industry Style: Defensive, Growth, Innovation

Declining

Fundamental Analysis FAQ